|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
[<sup>18</sup>F]-THK5351 PET was performed in 34 patients: six with Parkinson's disease (PD), nine with multiple system atrophy with predominant parkinsonism (MSA-P), six with MSA with predominant cerebellar ataxia (MSA-C), and 13 with progressive supranuclear palsy (PSP) Richardson's syndrome.
|
31572166 |
2019 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data obtained from 10 patients with clinical diagnosis MSA-P, 14 patients with CBS and 21 patients with PSP, which were analyzed using Tukey honest significant difference post-hoc test, revealed significant differences of perfusion P < .05 between MSA-P and PSP within the cerebellum and thalamus.
|
31348305 |
2019 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
When compared with HC, MSA and PSP patients shared the changes in PD, with a few exceptions: in MSA, Lachnospiraceae were not lower, and Prevotellaceae were reduced; in PSP, Lactobacillaceae were similar, and Streptococcaceae were reduced.
|
30576008 |
2019 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multimodal MRI improved the detection of disease-specific neurodegenerative patterns in PSP and MSA-P and highlights its potential to improve the diagnostic accuracy of atypical parkinsonian disorders.
|
31450511 |
2019 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<sup>123</sup>I-FP-CIT SPECT was performed at a single-center level on 370 individuals with PS, including 280 patients with Parkinson's disease (PD), 21 with multiple system atrophy-parkinsonian type (MSA-P), 41 with progressive supranuclear palsy (PSP) and 28 with corticobasal syndrome (CBS) (mean age 70.3 years, 47% female, mean disease duration at scan 1.4 year), as well as 208 age- and gender-matched control subjects.
|
31037416 |
2019 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We screened for NP-C 24 patients with Progressive Supranuclear Palsy and 10 with Multiple System Atrophy cerebellar type (MSA-C).
|
31221578 |
2019 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Magnetic Resonance Parkinsonism Index (MRPI) utilizes linear and surface (planimetry) measurements and has been proposed as a dual MRI biomarker, with high values indicative of PSP and low values of MSA.
|
29196955 |
2018 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was no significant difference in axial symptoms between PSP-RS and MSA-p, except for self-reported falls (more frequent in PSP-RS patients).
|
29910157 |
2018 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Twenty-five patients with Progressive Supranuclear Palsy - Richardson's Syndrome (PSP-RS), nine with cerebellar and nine with parkinsonian Multiple System Atrophy variants (MSA-C and MSA-P), forty-seven with Parkinson's Disease (PD) and twenty-seven HC underwent a 1.5 T brain-MR protocol including high-resolution 3D T1-weighted and 25-direction diffusion tensor imaging sequences.
|
28291592 |
2017 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The VOI analysis based on spatially normalized PRESTO images may be useful for depicting hypointensity, indicative of abnormal iron depositions, of the putamen and red nucleus in the diagnosis of MSA-P and PSP.
|
27001391 |
2017 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
We enrolled 34 de novo PD patients and 29 patients affected by atypical parkinsonisms (Multiple System Atrophy, MSA, n = 10; Progressive Supranuclear Palsy, PSP, n = 12 and Corticobasal Degeneration, CBD, n = 7) who underwent an acute levodopa challenge.
|
28207803 |
2017 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple system atrophy-cerebellar type and MSA-P groups show different regional uptake patterns compared with PD group on pCITs in quantitative and statistical parametric mapping analyses, analogous to FDG images, but not in the PSP group.
|
27922865 |
2017 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSP can thus be mistakenly diagnosed as MSA.
|
27861346 |
2016 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Around 48.3% of the MSA-P patients and 52.9% of the PSP patients showed symmetric symptoms.
|
20083340 |
2010 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To review the clinical and molecular features of non-Alzheimer's disease (non-AD) dementias, focusing on disorders associated with tau pathology (that is, frontotemporal lobar degeneration [FTLD], corticobasal ganglionic degeneration [CBD], and progressive supranuclear palsy [PSP]) or on disorders with synuclein pathology (that is, dementia with Lewy bodies [DLB] and multisystem atrophy [MSA]).
|
15101498 |
2004 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we used in situ hybridization to detect the common deletion in sections of midbrain from patients with PD, multiple system atrophy-parkinsonian type (MSA-P), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), age-matched controls, and individuals of different ages.
|
12039426 |
2002 |